HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells.

Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) have repeatedly shown to be effective in tumor prevention, but important side-effects limit their wide clinical use. Nitric oxide-releasing derivatives (NO-NSAIDs) are a promising class of compounds synthesized by combining a classic NSAID molecule with an NO-releasing moiety to counteract side-effects. These new chemical entities exhibit a significantly higher activity and much lower toxicity with respect to the parental drug. In the present paper, we report the results obtained from in in vitro experimental systems aimed to evaluate the activity and mechanisms of action of the novel NO-releasing aspirin derivative, NCX 4040. The in vitro studies were carried out on a panel of human colon (LoVo, LoVo Dx, WiDr, LRWZ), bladder (HT1376, MCR), and pancreatic (Capan-2, MIA PaCa-2, T3M4) cancer cell lines. With regard to colon cancer, NCX 4040 activity was also investigated in vitro in combination with drugs currently used in clinical practice and was validated in vivo on tumor-bearing mice xenografted with the aforementioned colon cancer cell lines. The in vitro studies showed a high cytotoxic activity of NCX 4040 in all tumor histotypes and demonstrated the pivotal role of the NO component in drug activity. It was also observed that NCX 4040 exerts a pro-apoptotic activity via a mitochondria-dependent pathway. Moreover, the in vivo studies on xenografted mice further confirmed the antitumor efficacy and low toxicity of NCX 4040 in colon cancer and highlighted its role as sensitizing agent of oxaliplatin cytotoxicity.
AuthorsAnna Tesei, Wainer Zoli, Francesco Fabbri, Carlo Leonetti, Marco Rosetti, Manlio Bolla, Dino Amadori, Rosella Silvestrini
JournalNitric oxide : biology and chemistry (Nitric Oxide) Vol. 19 Issue 2 Pg. 225-36 (Sep 2008) ISSN: 1089-8611 [Electronic] United States
PMID18472019 (Publication Type: Journal Article, Review)
Chemical References
  • NCX 4040
  • Nitric Oxide Donors
  • Nitro Compounds
  • Organoplatinum Compounds
  • Pyridines
  • oxiplatin
  • Aspirin
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Apoptosis (drug effects)
  • Aspirin (analogs & derivatives, pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Humans
  • Mice
  • Neoplasms (drug therapy, pathology)
  • Nitric Oxide Donors
  • Nitro Compounds (pharmacology, therapeutic use)
  • Organoplatinum Compounds (therapeutic use)
  • Pyridines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: